ONCONETIX INC (ONCO) Stock Price, Quote, News and Overview
NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
ONCO Quote, Performance and Key Statistics
ONCONETIX INC
NASDAQ:ONCO (2/4/2025, 8:00:02 PM)
Premarket: 0.63 -0.01 (-2.17%)0.644
+0.04 (+5.75%)
The current stock price of ONCO is 0.644 USD. In the past month the price decreased by -20.46%. In the past year, price increased by 286.09%.
ONCO Latest News, Press Releases and Analysis
These stocks are making the most noise in today's session.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Traders are paying attention to the gapping stocks in Monday's session.
Let's have a look at the gap up and gap down stocks in today's session.
These stocks that are showing activity before the opening bell on Monday.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
ONCO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About ONCO
Company Profile
Onconetix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. Onconetix, Inc. is a commercial stage biotechnology company. The company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
Company Info
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 12
Company Website: https://onconetix.gcs-web.com/
Investor Relations: https://ir.bwbioinc.com/
Phone: 15136204101
ONCO FAQ
What is the stock price of ONCO?
The current stock price of ONCO is 0.644 USD.
What is the symbol for ONCONETIX INC stock?
The exchange symbol of ONCONETIX INC is ONCO and it is listed on the Nasdaq exchange.
On which exchange is ONCO stock listed?
ONCO stock is listed on the Nasdaq exchange.
Is ONCO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ONCO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ONCO.
Does ONCO stock pay dividends?
ONCO does not pay a dividend.
What is the Price/Earnings (PE) ratio of ONCO?
ONCO does not have a PE ratio as the earnings reported over the last twelve months were negative (-95.63).
What is the Short Interest ratio of ONCO stock?
The outstanding short interest for ONCO is 4.39% of its float.
ONCO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ONCO. When comparing the yearly performance of all stocks, ONCO is one of the better performing stocks in the market, outperforming 97.27% of all stocks.
ONCO Financial Highlights
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -95.63. The EPS decreased by -8438.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.34% | ||
| ROE | -152.17% | ||
| Debt/Equity | 0.29 |
ONCO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ONCO. The Buy consensus is the average rating of analysts ratings from 6 analysts.